---
title: "PharmaResources (Shanghai) Co., Ltd. (301230.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/301230.SZ.md"
symbol: "301230.SZ"
name: "PharmaResources (Shanghai) Co., Ltd."
industry: "Life Sciences Tools and Services"
---

# PharmaResources (Shanghai) Co., Ltd. (301230.SZ)

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Location | CN Market |
| Website | [www.pharmaresources.cn](https://www.pharmaresources.cn) |

## Company Profile

PharmaResources (Shanghai) Co., Ltd. engages in new drug research, development, and commercial production in China. It offers small molecule drug CRO, CDMO, and CMO. The company also involved in drug discovery, research, and development of pharmaceutical processes; and customized and commercial prod...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-18T04:30:10.000Z

**Overall: B (0.31)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 8 / 27 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 29.88% |  |
| Net Profit YoY | 428.07% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 6.15 |  |
| Dividend Ratio | 1.09% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6.31B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 667.45M |  |


**Multi Score**: B

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3.53% | C |
| Profit Margin | 5.48% | C |
| Gross Margin | 29.87% | C |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 29.88% | A |
| Net Profit YoY | 428.07% | A |
| Total Assets YoY | -3.87% | D |
| Net Assets YoY | -1.76% | D |

#### Cash Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 1824.23% | A |
| OCF YoY | 29.88% | A |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.50 | C |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 21.40% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - PharmaResources (Shanghai) Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "3.53%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "5.48%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "29.87%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "29.88%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "428.07%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-3.87%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-1.76%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "A",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "1824.23%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "29.88%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.50",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "21.40%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | WuXi AppTec (SH.603259) | A | A | C | B | B | B |
| 02 | Pharmaron (SZ.300759) | B | B | C | C | B | B |
| 03 | Chemexpress (SH.688131) | B | A | C | C | B | B |
| 04 | HitGen (SH.688222) | B | B | D | B | B | B |
| 05 | Sepax Technologies (SH.688758) | C | B | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 172.48 | 16/27 | 219.75 | 185.87 | 146.85 |
| PB | 6.15 | 24/27 | 5.10 | 4.52 | 4.13 |
| PS (TTM) | 9.45 | 19/27 | 9.44 | 7.92 | 7.01 |
| Dividend Yield | 1.09% | 2/27 | 1.27% | 1.13% | 1.02% |

## Institutional View

### Analyst Rating Distribution

> As of 2025-06-05T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 45.21 |

## References

- [Company Overview](https://longbridge.com/en/quote/301230.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/301230.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/301230.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.